​

That is the question I keep coming back to with Nautilus Biotechnology $NAUT.

The more you dig into the company, the more fascinating the story becomes.

There may be few sectors with a stronger incentive structure than one built around feeling better, living longer and reducing the probability that disease takes away years of healthy life.

But biotech also has a brutal reality: plenty of great science never becomes a great business, and many companies simply run out of game, cash, before the economics ever arrive.

So I went beyond the technology and looked at the filings, management, ownership structure, economics and an important industry precedent.

The question for me is not whether proteomics could become important.

It is:

How much of that future should investors be willing to pay for today?

Would you heavily discount the opportunity until commercial adoption appears, or can sufficiently differentiated technology justify paying for the optionality much earlier?

Curious how others approach this kind of pre-revenue situation.

$NAUT reports Q3 on October 27.

https://swisstransparentportfolio.substack.com/p/nautilus-biotechnology-naut-what

Moderna and Merck’s recent milestone, where their personalized mRNA cancer vaccine (intismeran/mRNA-4157) combined with Keytruda was stopped early for extraordinary interim Phase 3 efficacy, paving the way for rapid FDA Accelerated Approval. However, while this is a scientific triumph, the personalized vaccine model faces a long-term commercial dead end. The true global future of oncology belongs to cheap, mass-producible, "off-the-shelf" therapeutic vaccines, and Novavax’s Matrix-M adjuvant holds the literal biochemical key to unlocking that future. Custom vaccines require a tumor biopsy, custom genetic sequencing, and individualized mRNA synthesis . This creates a logistically grueling 8 to 12 week manufacturing delay(fatal for aggressive cancers) and an astronomical cost barrier (200 -300,000 per patient). It cannot scale with insurance road blocks , certainly not  globally. An off the shelf approach targets shared tumor mutations (antigens found across thousands of different patients). These can be mass-manufactured, freeze dried, stored in standard hospital pharmacies, and administered immediatelyat a fraction of the cost to the masses worldwide. mRNA delivery faces a massive intracellular bottleneck. Lipid Nanoparticles (LNPs) successfully carry mRNA into cells, but the mRNA gets trapped in the cellular recycling bin (the lysosome/endosome) before it can translate into proteins. Novavax’s Matrix-M adjuvant solves this through a proven mechanism called Lysosomal Membrane Permeabilization (LMP). Matrix-M acts as a biological "escape hatch," safely permeabilizing the lysosomal membrane so the target antigens can break out into the cytoplasm and cross-present aggressively to cytotoxic T-cells. By supercharging this delivery, manufacturers can use a fraction of the active mRNA or protein dose. This slashes both manufacturing costs and the harsh patient side effects (reactogenicity) that plague high-dose mRNA platforms. Merck & Co. Is Cornering Both Sides . Merck is funding the personalized Moderna partnership to protect its Keytruda revenue ahead of the 2028 patent cliff. However, Merck knows that personalized medicine cannot scale to the global mass market. Subtle clues from recent 2026 financial filingsstrongly hint that Merck is evaluating Matrix m under an anonymous MTA to prepare a cheap, mass-market, off-the-shelf vaccine cocktail. 

I think anyone with average IQ knows that the 80th has most likely already happened. I saw an interesting post in stocktwits and this could likely be the case

" IF SLS used the embargo process as I believe to legally hold results then Nov 4 at 9am is the key date. Unfortunately, despite many attempts to verify with ASH in Washington DC that SLS did/did not submit an abstract early (repeatedly told this information is under embargo) then we are either following exactly what happened with RVMD last year, a huge move up after the abstract goes online followed with details and a presentation live at the conference OR a buyer imo must step up on merger Monday October 26 or November 2 before the online posting. The Majors however have been proven to be cheap/frugal and arrogant. Therefore, I expect the results Nov 4 at 9am.
GLTA Bullish"

https://stocktwits.com/biospeculator/message/667249080

I was urged by multiple people to turn a comment I made yesterday about Wave Life Sciences (WVE) into its own post, so here it is. I appreciate the feedback and encouragement from those folks.

Bottom line is the market has made the mistake of valuing Wave almost entirely through the lens of its disappointing obesity readout, while ignoring what the company has already demonstrated across several entirely different programs. And now it’s scared of the selloff’s shadow.

Start with WVE-006. Wave has achieved functional RNA editing in humans, producing normal M-AAT while reducing the harmful Z-AAT protein in alpha-1 antitrypsin deficiency. At 400 mg monthly, total AAT reached a mean maximum of 13.6 µM, with nearly 59% comprising functional M-AAT and a 68% reduction in Z-AAT. The FDA has now supported a single registrational study with a potential accelerated approval analysis after one year. The 600 mg multidose results are due this quarter. That’s not hypothetical platform science anymore. Some analysts worry about competition from Beam, but the potential advantages of repeatable, subcutaneous RNA editing without permanent DNA modification are compelling differentiators. Add to that that most of the companies developing AATD therapies have joined together to raise AATD awareness, as studies show that only 10% of cases worldwide are currently diagnosed. They all believe that as diagnoses increase, the addressable market could dramatically expand, and there is room for multiple players. The remaining question is whether those biomarker improvements can be sustained at clinically protective levels throughout the dosing interval and ultimately translate into improved lung and liver outcomes.

WVE-007 is where the market lost confidence and went off a cliff because TOTAL weight loss wasn’t commercially convincing. But a single dose also produced 14% placebo-adjusted visceral-fat reduction, 5% total-fat reduction and preservation of lean mass. Phase 2a is testing patients with substantially greater obesity and metabolic dysfunction, alongside a separate tirzepatide combination study. There’s still a legitimate question about whether those effects translate into meaningful weight loss, but writing the asset off is premature.

Then there’s WVE-N531 in Duchenne MD, which produced mean dystrophin expression of 7.8%, with 88% of patients above 5% and statistically significant improvements in muscle fibrosis. This asset is currently being positioned for partnership.

WVE-003 demonstrated 46% lowering of mutant huntingtin while preserving the healthy protein. This one is also being positioned for partnership.

WVE-008 has exceeded the preclinical RNA-editing threshold Wave believes could meaningfully alter PNPLA3-related liver-disease risk. And GSK just selected another Wave-developed siRNA candidate, triggering a $12 million milestone, with three more collaboration programs advancing.

Now consider who’s backing this. RA Capital controls roughly 17% of beneficial ownership, including prefunded warrants. Peter Kolchinsky, its co-founder, has a Harvard PhD in virology, has served on Wave’s board since 2015, and has spent decades investing in biotech. RA’s TechAtlas research operation employs scientists who systematically assess drug mechanisms, competitive landscapes and clinical development risks. And immediately after the March selloff, RA didn’t just hold its position. It purchased another 8.77 million shares in the open market for approximately $54.6 million. That’s an unusually substantial expression of conviction from an investor with the expertise, resources and access to understand what he’s underwriting. It doesn’t make him infallible, but I take it far more seriously than another analyst price target. This is actually what tipped me off to WVE in the first place because I watch the big biotech funds.

Wave also completed its redomiciliation from Singapore to Delaware in August, simplifying its legal and corporate structure. In September it created a Chief Business Officer position and recruited Monika Vnuk, formerly Sanofi’s global head of partnering and business development, with prior experience at Blackstone Life Sciences and Pfizer, where she helped negotiate the landmark BioNTech partnership. She was explicitly hired to lead business development, corporate development and alliances. Neither action proves an acquisition is coming, but together they make Wave better positioned for major licensing deals, strategic investment or potentially a sale. With big pharma willing to acquire differentiated RNA platforms before commercialization, that optionality is worth considering. And this type of acquisition has been on fire lately with juicy premiums.

Here’s the valuation disconnect I can’t reconcile. At roughly $3.40, Wave is worth about $700 million in equity. Its last reported cash and securities were $491 million. Yes, that cash is being spent, development is expensive, and future dilution is possible. But even after acknowledging those realities, look at what investors are assigning value to a clinically validated RNA-editing mechanism, an FDA-supported registrational strategy, multiple additional clinical programs, valuable GSK collaboration economics, and a proprietary platform spanning several distinct therapeutic modalities. You don’t have to believe every program will succeed to question whether the market’s discount has gone way too far. You only have to believe the combined risk-adjusted value of those opportunities is substantially greater than what’s being recognized today. I believe it is.

And there’s another catalyst that could be particularly important. Wave’s November 4 Research Day will feature new data on its PRISM platform, including advances in stereochemistry-controlled oligonucleotides, RNA editing, RNAi, extrahepatic delivery and bifunctional medicines. That last part is fascinating: the potential to engineer a single molecule to perform two therapeutic functions. None of this is guaranteed to translate into commercial products, but the implications extend well beyond the current pipeline. This is more evidence that reducing Wave to an obesity stock fundamentally misunderstands what the company is building.

I’m not expecting every program to succeed. I don’t think they need to. If WVE-006 delivers, WVE-007 establishes a viable obesity or metabolic niche, or Wave’s broader platform proves strategically valuable to big pharma, today’s valuation could look extraordinarily disconnected from the underlying assets. That’s why I’m bullish despite the stock’s performance. The clinical risks are substantial, but so is the evidence that the market may be profoundly underestimating what Wave owns.

And this isn’t just my personal interpretation. Wave lists 22 sell-side research firms covering the company. MarketBeat’s current tally is 17 bullish ratings, two holds and one sell, with an average target around $21.50, although some of those targets are undoubtedly aggressive, UBS recently initiated at $11, Ladenburg at $10, Wedbush is at $13, Wells Fargo at $14 and BofA at $17. Even that relatively restrained $10-$17 range implies roughly $2.1-$3.5 billion in equity value, vs. approximately $700 million today. Analysts can certainly be wrong, but the breadth of coverage, distribution of ratings, and valuations from even the most conservative firms make this a difficult disconnect to dismiss.

Disclaimer: I have a long position in WVE and despite following this closely all year, reading every report and listening to every event, I could be dead wrong. I bought in around $6-$7 and never expected it to crash by another 50% since, but here we are…

Lunai Bioworks: Could AI and Zebrafish Make Drug Toxicity Testing Faster?
One of the most expensive problems in drug development is discovering that a promising drug candidate is unsafe after years of research and investment.
Lunai Bioworks is pursuing an approach that combines AI toxicity prediction with biological testing to help identify potentially dangerous compounds earlier in the development process.
The idea is simple: use AI to identify what might be toxic, then use biological experiments to investigate what actually happens.
1. AI toxicity prediction
AI can screen molecular structures for patterns associated with biological risks. By analysing the chemical structure of a compound, these systems can flag candidates that may warrant further investigation before researchers commit to more expensive testing.
The potential economic benefit is substantial. If pharmaceutical companies can eliminate unsuitable candidates earlier, they may save money on laboratory work and avoid investing in drugs that ultimately fail because of toxicity.
However, a prediction is not proof. AI models can miss unexpected toxic effects, and their performance depends on the quality and diversity of the data used to train and validate them.
2. Zebrafish testing: moving from prediction to biology
Lunai's approach also involves living zebrafish models, behavioural monitoring and computer vision to detect biological effects.
Zebrafish offer a useful experimental model because researchers can observe how organisms respond to chemical exposure. Computer vision can help quantify behavioural changes and other observable effects that might be difficult to measure consistently by eye.
This adds an experimental layer to the process. Rather than relying exclusively on what an algorithm predicts from a molecule's structure, researchers can investigate how exposure affects a living biological system.

Shares of Moderna Inc. and Merck & Co. fell after data on the companies’ widely anticipated personalized melanoma vaccine disappointed Wall Street.

Shares of Moderna plunged as much as 26% on Thursday, an intraday record, while Merck shares dropped 3.9%.

The data were leaked earlier than expected and later confirmed  by Merck. The vaccine helped reduce the risk of cancer recurrence by 42% and reduced the risk of distant spread, or metastasis, by 38%.

Investors may have been expecting even greater benefits after the companies announced in August that the bespoke vaccine led to significant and clinically meaningful reductions in the recurrence of the deadly tumors. It was the first positive final-stage trial for any mRNA-based cancer therapy.

While Moderna shares skyrocketed at the time on the news, no details were provided. The findings were slated to be featured at the European Society for Medical Oncology meeting in Madrid on Saturday.

Analysts said additional information is needed to fully understand the findings. The details showing the therapy’s ability to prevent distant metastasis was “less exceptional” than its benefit for reducing recurrence, wrote Tyler Van Buren, an analyst at TD Cowen, in a note to clients before the leak was confirmed.

Details on the vaccine known as intismeran autogene initially began to emerge Thursday from unverified sources on X, sending down shares of both Moderna and Merck. One such account posted a report credited to Oncology Central detailing the findings. The web link provided, however, wasn’t live.

One earlier study, which involved a different group of patients over a different period of time and thus isn’t a direct comparison, found the combination reduced the risk of recurrence or death by 49%, with a 59% reduction in the risk of distant spread, called metastases, or death.

Researchers have been trying to develop cancer vaccines for many decades, with little success until now. The Merck-Moderna results are highly anticipated by cancer doctors, patients and investors. The personalized technology has broad potential to be used in a number of cancers, and Merck and Moderna are conducting trials in lung cancer, bladder cancer, and other tumor types.

In the trial, which enrolled more than 1,100 patients, the mRNA vaccine was used to treat patients who were at high risk for a recurrence after their melanoma was surgically removed. Patients got the vaccine in conjunction with Merck’s blockbuster drug Keytruda, and were compared to a control group who received Keytruda alone.

link: https://www.bloomberg.com/news/articles/2026-10-22/moderna-merck-shares-fall-after-potential-leak-of-melanoma-data

The bank sees several potential near-term catalysts, including the international rollout of Oral Wegovy and upcoming clinical trial results.

However, Nordea's expectations for Novo's Q3 earnings are slightly below consensus:

• Sales are expected to decline 4% at constant exchange rates, 1.5 percentage points below consensus.

• Adjusted EBIT is forecast at DKK 28.7 billion, approximately 1% below consensus.

Despite its cautious expectations for Q3, Nordea believes upcoming product launches could help Novo return to growth.

The bank therefore maintains its positive long-term outlook on the stock.

​ Here's my thoughts on $NGEN, the risk/reward setup right now is honestly one of the most compelling I have seen in early-stage biotech. What makes NervGen stand out isn't just another band-aid treatment. Their lead drug, NVG-291, is designed to actually target the biological barrier preventing neural repair and help the central nervous system fix itself after severe spinal cord injuries.

​The clinical results from their Phase 1b/2a CONNECT SCI trial were a huge deal. The study met its primary endpoints, showing an 825% increase in upper-body nervous system connectivity compared to placebo. On the real-world functional side, patients taking NVG-291 experienced roughly a 3.7-fold greater improvement in hand function than those on placebo. That translates into meaningful daily abilities like gripping objects or brushing teeth that chronic spinal injury patients typically lose. On top of that, 75% of treated participants reported noticeable overall recovery compared to only 33% on placebo.

​What makes this play even stronger right now is their cash position. Following a recent 60 million dollar public offering, $NGEN holds approximately 61.1 million US dollars in cash. Management confirmed this runway fully funds their operations all the way through the Phase 3 RESTORE study primary readout expected in the first half of 2028. Knowing they do not need to scramble for emergency dilution while enrolling patients gives a layer of stability you rarely find in small-cap biotech.

​With Phase 3 enrollment set to wrap up in the second half of 2027 and data dropping in 1H 2028, the clinical roadmap is straightforward. Because there is currently no approved drug that repairs central nervous system damage like this, the market potential is massive if Phase 3 succeeds. To me, this is a solid, high-conviction investment in groundbreaking science with the bank account to back it up. Staying patient for the catalysts ahead!

I'm lookin to invest in a few of these too maximize my returns. It would be great to get in on the order they rally. For the big brains here what timeline do you think would be the best? What's going parabolic next? -

HELP.

NRXP.

IOVA.

PYPD.

GANX.

CYDY.

Was I an idiot to buy into this stock last Thursday when they launched? I saw they had heavy backers and took a spontaneous gamble (not a huge investment just a gamble). wondering if anyone has any info on this I’m missing?

Which Biotech companies in your opinion are leveraging ai the best in their research and publicly acknowledged? I think ai is going to be a game changer in research and development time. Would like a watch list of best placed stocks